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Abstract
Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, we 
analyzed 1,404 UCBT patients [single (< 18 years) = 810, double (≥ 18 years) = 594] with acute 
leukemia to define the incidence of acute and chronic graft-vs.-host disease (GVHD), analyze 
clinical risk factors and investigate outcomes. After single UCBT, 100-day incidence of grades II–
IV aGVHD was 39% (95% CI, 36–43%), grades III–IV aGVHD was 18% (95% CI, 15–20%), and 
1-year cGVHD was 27% (95% CI, 24–30%). After double UCBT, 100-day incidence of grades II–
IV aGVHD was 45% (95% CI, 41%–49%), grades III–IV aGVHD was 22% (95% CI, 19–26%), 
and 1-year cGVHD was 26% (95% CI, 22–29%). For single UCBT, multivariate analysis showed 
that absence of anti-thymocyte globulin (ATG) was associated with aGVHD, whereas prior 
aGVHD was associated with cGVHD. For double UCBT, absence of ATG and myeloablative 
conditioning were associated with aGVHD, while prior aGVHD predicted for cGVHD. Grades 
III–IV aGVHD led to worse survival whereas cGVHD had no significant effect on disease-free or 
overall survival. GVHD is prevalent after UCBT with severe aGVHD leading to higher mortality. 
Future research in UCBT should prioritize prevention of GVHD.
Keywords
GVHD; umbilical cord blood; allogeneic transplantation
INTRODUCTION
Acute and chronic graft-vs.-host disease (GVHD) are significant complications after 
allogeneic hematopoietic stem cell transplantation (HSCT). Many recent changes in practice 
have led to changing patterns of GVHD. These include the introduction of alternative donor 
sources, reduced intensity conditioning and novel prophylaxis for GVHD. Risk factors for 
and effects on outcomes from GVHD have been described for conventional adult donor 
HSCT.1
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Umbilical cord blood (UCB) has emerged as an alternative donor source with the 
development of new protocols which have significantly improved outcomes.2 It is unclear if 
acute and chronic GVHD after UCBT has similar risk factors and effects on outcomes 
compared to conventional donor sources. In this study, we proposed to establish the 
incidence of clinically significant acute and chronic GVHD after UCBT, analyze the risk 
factors which are associated with its development and investigate the influence of acute and 
chronic GVHD on patient outcomes after UCBT.
METHODS
Data Source
The Center for International Blood and Marrow Transplant Research (CIBMTR) registry 
includes a voluntary working group of more than 450 centers worldwide that contribute 
detailed data on consecutive allogeneic and autologous hematopoietic cell transplantations to 
a statistical center at the Medical College of Wisconsin in Milwaukee and the National 
Marrow Donor Program (NMDP) Coordinating Center in Minneapolis. Participating centers 
are required to report all transplants consecutively; patients are followed longitudinally and 
compliance is monitored by on-site audits. Computerized checks for discrepancies, 
physicians’ review of submitted data and on-site audits of participating centers ensure data 
quality. Observational studies conducted by the CIBMTR are performed in compliance with 
all applicable federal regulations pertaining to the protection of human research participants. 
Protected Health Information used in the performance of such research is collected and 
maintained in CIBMTR’s capacity as a Public Health Authority under the HIPAA Privacy 
Rule.3
Patient Selection
All patients who underwent UCBT for acute myeloid leukemia (AML) and acute 
lymphoblastic leukemia (ALL) between 2003 and 2012 and reported to CIBMTR were 
included initially (n=2,663). Cases were then excluded for several reasons including: related 
UCB units (n=51), ex vivo expanded units (n=84), ex vivo TCD (n=7), lack of research 
consent (n=24), lack of conditioning (n=4), lack of GVHD prophylaxis (n=49), use of non-
myeloablative conditioning (n=4), use of ≤ 3/6 HLA-matched UCB units (n=40), lack of 
calcineurin inhibitor (n=68), missing HLA-matching data (n=18) and use of alemtuzumab 
(n=8). Based on numbers of cases and standard practice, only recipients of double UCBT ≥ 
18 years old (excluded 206 recipients < 18 years of age) who received myeloablative or 
reduced intensity conditioning, and only recipients of single UCBT < 18 years old (excluded 
247 recipients ≥ 18 years of age) who received myeloablative conditioning were included. 
HLA-match status was based on intermediate resolution for HLA-A and B and high 
resolution for HLA-DRB1. In the context of double UCBT, data on specific cord unit 
dominance was not available. For purposes of analysis of double UCBT, HLA-matching 
(relative to the recipient) was analyzed using the following categories of double cord blood 
combinations: 1) 4/6 + 4/6, 2) 4/6 + ≥ 5/6, and 3) ≥ 5/6 + ≥ 5/6. Disease status at transplant 
was defined as early (first complete remission), intermediate (second, or greater, complete 
remission) and advanced (presence of active disease).
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Study Endpoints
The diagnoses of acute and chronic GVHD were reported by the treating center. Acute 
GVHD was diagnosed and graded per previously published consensus guidelines.4 Chronic 
GVHD was diagnosed according to Seattle criteria5 as the National Institutes of Health 
(NIH) consensus criteria6 had not yet been implemented on CIBMTR forms during this time 
period. Overall survival considered death from any cause as the event, and surviving patients 
were censored at the date of last contact. Disease free survival was defined as survival 
without relapse or death from any cause, with patients who were alive and in complete 
remission censored at the time of last follow-up. Non-relapse mortality (NRM) was defined 
as death during a continuous complete remission. Relapse was defined as recurrence of the 
primary disease.
Statistical Analysis
Chi-square or Fisher’s exact tests were used to compare frequencies for categorical 
variables, and ANOVA (analysis of variance) was used to compare means for continuous 
variables in different subsets. Univariate probabilities for overall survival were calculated 
using the Kaplan-Meier estimator.7 Comparison of survival curves was made by the log-rank 
test. The cumulative incidences of acute GVHD and chronic GVHD were calculated by 
treating death as a competing risk.8 Multivariate analysis was performed using Cox 
proportional hazards models for OS, progression-free survival (PFS), relapse, NRM, acute 
GVHD and chronic GVHD. All the clinical variables were first tested for affirmation of the 
proportional hazards assumption. Factors that violate the proportional hazards assumption 
were adjusted through stratification. Then a stepwise model building procedure was used to 
develop models for each outcome with a threshold of 0.05 for both entry and retention in the 
model. We also assessed the effects of acute GVHD II–IV, acute GVHD III–IV and chronic 
GVHD on OS, progression-free survival, relapse and NRM by forcing acute GVHD II–IV, 
acute GVHD III–IV or chronic GVHD into the multivariable models as a time-dependent 
variable. Center effect was also adjusted in all of the multivariable models. SAS version9.3 
(SAS Institute, Cary, NC) was used for all the analyses.
RESULTS
Clinical Characteristics
A total of 810 recipients of single UCBT and 594 recipients of double UCBT were included. 
Patient and clinical characteristics are summarized in Table 1a. For the 810 recipients of 
single UCBT, median age was 6 (range, <1–18). 44% of patients had AML, 56% had ALL 
and all received myeloablative conditioning. 21% of patients received a 6/6 HLA-matched 
UCBT, 47% received a 5/6 HLA-matched UCBT and 32% received a 4/6 HLA-matched 
UCBT. All patients received calcineurin inhibitor-based GVHD prophylaxis. Anti-
thymocyte globulin (ATG) was used in 64% of patients. Table 1a shows differences between 
patients who received ATG compared to those who did not.
For the 594 recipients of double UCBT, median age was 42 (range, 18–79). 72% of 
recipients had AML and 28% had ALL. 59% of patients received myeloablative 
conditioning while 41% received reduced intensity conditioning. 26% received a 5/6 + 5/6-
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matched combination, 21% received a 5/6 + 4/6 combination, 42% of recipients received a 
4/6 + 4/6 combination, and 10% received combinations including a 6/6 UCB unit. All 
patients received calcineurin inhibitor-based GVHD prophylaxis. ATG was employed in 
21% of patients. Table 1b shows differences between patients who received ATG compared 
to those who did not.
Single UCBT - GVHD
After single UCBT, the cumulative incidence at of grades II–IV and grades III–IV acute 
GVHD at 100 days was 39% (95% CI, 36%–43%) and 18% (95% CI, 15%–20%), 
respectively (Table 2). Median time to acute GVHD was 25 days (range, 3–211). 
Multivariate analysis showed that absence of ATG was the only significant factor associated 
with grades II–IV (HR 1.56, 95% CI 1.21–2.01, p = 0.0006) (Figure 1). No significant 
factors were associated with grades III–IV acute GVHD. Notably, the following were not 
associated with acute GVHD: age, race, gender, CMV serostatus, HLA-matching, TNC 
dose, year of transplant, underlying disease, total body irradiation (TBI) and GVHD 
prophylaxis regimen. Given the clinical differences between recipients of ATG and those 
who did not, we performed this analysis in patients who did not receive ATG. In this subset, 
no factors were significantly associated with the development of acute GVHD.
After single UCBT, the cumulative incidence of chronic GVHD was 27% (95% CI, 24%–
30%) at one year and median time to chronic GVHD was 5.3 months. Multivariate analysis 
showed that prior acute GVHD (HR 2.02, 95% CI, 1.51–2.70, p<0.0001) was the only 
significant factor associated with chronic GVHD. Notably, absence of ATG was not 
significantly associated with the development of chronic GVHD (HR 1.05, 95% CI, 0.76–
1.44, p=0.78).
Double UCBT – GVHD
For recipients of double UCBT, the cumulative incidence at day 100 of grades II–IV and 
grades III–IV acute GVHD was 45% and 22%, respectively. Median onset to acute GVHD 
was 26 days (range 6–380). Multivariate analysis demonstrated that absence of ATG was 
associated with grades II–IV acute GVHD (HR 2.33, 95% CI 1.54–3.52, p = 0.0001) (Figure 
2), but not with grades III–IV acute GVHD (HR 1.28, 0.89–1.84, p = 0.17). In addition, 
reduced intensity conditioning protected from both II–IV (HR 0.73, 95% CI 0.56–0.95, p = 
0.019) and III–IV (HR 0.63, 95% CI 0.44–0.92, p = 0.016) acute GVHD. Notably, the 
following factors were not associated with acute GVHD: age, gender, CMV serostatus, 
HLA-matching, TNC dose, underlying disease, TBI, year of transplant and GVHD 
prophylaxis regimen. In patients who did not receive ATG, no factors were shown to be 
significantly associated with acute GVHD.
For all recipients of double UCBT, the cumulative incidence of chronic GVHD was 26% 
(95% CI, 22%–29%) at one year. Median time to chronic GVHD was 5.3 months. 
Multivariate analysis showed that prior acute GVHD (HR 2.12, 95% CI, 1.52–2.95, p 
<0.0001) was associated with chronic GVHD, while ATG had no significant effect.
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Single UCBT – Effect of GVHD on NRM, Relapse, DFS, OS
For all recipients of single UCBT, the development of grades II–IV acute GVHD (HR 2.06, 
95% CI 1.47–2.88, p < 0.0001) and grades III–IV acute GVHD (HR 2.75, 95% CI 1.92–
3.93, p < 0.0001) were associated with increased NRM. For disease relapse, grades II–IV 
acute GVHD was protective (HR 0.69, 95% CI 0.51–0.93, p = 0.014) while grades III–IV 
disease had no significant effect (HR 0.78, 95% CI 0.53–1.15, p = 0.22). For DFS, the 
development of grades II–IV acute GVHD has no effect (HR 1.06, 95% CI 0.86–1.32, p = 
0.58) while grades III–IV disease was associated with shorter DFS (HR 1.38, 95% CI 1.07–
1.79, p = 0.014). Similarly, for OS, grades II–IV acute GVHD had no effect (HR 1.08, 95% 
CI 0.87–1.34, p = 0.50) while grades III–IV disease was associated with shorter survival 
(HR 1.51, 95% CI 1.17–1.95, p = 0.0017) (see Table 3a). When analyzed independently, 
grade II acute GVHD did not have a significant effect on DFS or OS compared to those 
without acute GVHD (HR 0.74, 95% CI 0.55–0.99, P=0.045 for OS; HR 0.77, 95% CI 0.57–
1.03, p=0.08 for DFS). Compared to patients with grade III–IV acute GVHD, patients with 
grade II disease had similar rates of relapse, but less NRM and improved DFS and OS (data 
not shown). After single UCBT, chronic GVHD led to a higher risk of NRM (HR 1.53, 95% 
CI 0.97–1.90, p = 0.022) but no effect on relapse (HR 1.10, 95% CI 0.74–1.63, p = 0.63), 
DFS (HR 1.23, 95% CI 0.91–1.65, p = 0.18) and OS (HR 0.96, 95% CI 0.72–1.29, p = 0.82) 
(see Table 3a). Table 3b shows full results of the multivariate modeling.
Double UCBT – Effect of GVHD on NRM, Relapse, PFS, OS
For all recipients of double UCBT, the development of grades II–IV acute GVHD (HR 1.41, 
95% CI 1.05–1.90, p = 0.022) and grades III–IV acute GVHD (HR 2.24, 95% CI 1.66–3.04, 
p < 0.0001) were associated with increased NRM. In terms of disease relapse, neither grades 
II–IV acute GVHD (HR 0.87, 95% CI 0.63–1.20, p = 0.39) nor grades III–IV disease (HR 
0.68, 95% CI 0.44–1.06, p = 0.084) had any significant impact. Concerning DFS, the 
development of grades II–IV acute GVHD had no effect (HR 1.11, 95% CI 0.90–1.37, p = 
0.34) while grades III–IV disease was associated with shorter DFS (HR 1.41, 95% CI 1.11–
1.79, p = 0.005). Similarly, for OS, grades II–IV acute GVHD had no effect (HR 1.05, 95% 
CI, 0.86–1.30, p = 0.60) while grades III–IV disease was associated with shorter survival 
(HR 1.48, 95% CI, 1.17–1.86, p = 0.001) (see Table 3a). When analyzed independently, 
grade II acute GVHD did not have a significant effect on DFS (HR 0.80, 95% CI, 0.60–1.06, 
p = 0.12) but did lead to improved OS (HR 0.69, 95% CI, 0.52–091, p = 0.0084) when 
compared to those without acute GVHD. Compared to patients with grades III–IV disease, 
patients with grade II acute GVHD had similar rates of relapse, but had significantly less 
NRM and improved DFS and OS (data not shown). For all recipients of double UCBT, 
chronic GVHD showed a borderline significant association with a higher risk of NRM (HR 
1.49, 95% CI, 0.98–2.29, p = 0.065) and a significantly lower relapse (HR 0.59, 95% CI 
0.36–0.96, p= 0.033), but had no significant effect on DFS (HR 0.98, 95% CI 0.71–1.33, p = 
0.87) or OS (HR 0.95, 95% CI 0.71–1.27, p = 0.70) (see Table 3a). Table 3b shows full 
results of the multivariate modeling.
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DISCUSSION
We performed a large registry analysis using the CIBMTR database to define the incidence 
of acute and chronic GVHD, the clinical factors associated with their development and the 
effect of GVHD on outcomes after pediatric single and adult double UCBT. Our results 
confirm that the incidence of acute GVHD after UCBT is comparable to that observed with 
conventional donor sources7, but the incidence of chronic GVHD appears to be less, which 
has been reported previously.8,9
In our study, for pediatric recipients of single UCBT, the absence of ATG was significantly 
associated with the development of grades II–IV acute GVHD. Prior acute GVHD was 
associated with chronic GVHD. In the setting of adult double UCBT, the absence of ATG 
and myeloablative conditioning were associated with grades II–IV acute GVHD while prior 
acute GVHD was associated with chronic GVHD. As expected, severe acute GVHD resulted 
in increased NRM and decreased DFS and OS after both single and double UCBT. After 
single UCBT, the development of chronic GVHD appeared to increase NRM; whereas after 
double UCBT, chronic GVHD was associated with less disease relapse. Yet, chronic GVHD 
clearly had no significant effect on DFS and OS.
Several retrospective analyses have previously attempted to define risk factors for acute and 
chronic GVHD after UCBT and these are summarized in Tables 4a and 4b, respectively. 
Similar to our analysis, lack of ATG and myeloablative conditioning have been associated 
with acute GVHD in other studies,10–12 yet unlike our study, degree of HLA-matching has 
also been shown to be influential.10,12,13 For chronic GVHD, as observed in our analysis, 
prior acute GVHD has been shown to be the most important factor,10–12,14 and several 
groups have also reported the association of higher HLA-mismatch with chronic 
GVHD.10,12,14
Our study represents the largest study of UCBT patients investigating risk factors for acute 
and chronic GVHD, as well as the effect that acute and chronic GVHD has on long-term 
outcomes. The use of ATG appeared to be the most significant factor associated with acute 
GVHD after both single UCBT and double UCBT. It is important to note that our analysis 
did not distinguish different types of ATG, incorporate information on the dose or schedule 
employed as well as accompanying systemic corticosteroids given or report the rationale 
behind why treating physicians chose to use ATG. It is interesting that use of ATG was not 
significantly associated with chronic GVHD after single or double UCBT and this may 
reflect a significant difference between UCBT and other donor sources. After multivariate 
analysis, ATG had no significant effect on PFS or OS after single or double UCBT. While 
the overall effect of ATG was not a primary objective of this study, we do believe that future 
analyses are warranted with a focus on other important endpoints not collected here such as 
graft failure, specific infections and post-transplant lymphoproliferative disease. The use of 
ATG in UCBT is controversial as recent studies have suggested a benefit in terms of 
protection from GVHD,15,16 while other studies have shown that ATG is associated with an 
increase in overall mortality.17–19
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Interestingly, the degree of HLA-mismatch was not a significant factor in our multivariate 
analysis for single UCBT, and we could not analyze this factor accurately in double UCBT 
due to missing information on specific cord unit dominance. Other limitations of our 
analysis include those inherent to any large registry analysis including heterogeneity of 
practice. Specifically, for studies involving GVHD, the diagnosis does not undergo rigorous 
central review. This point is emphasized by a recent analysis describing characteristics of 
chronic GVHD in 87 patients undergoing UCBT at a single center. After review of medical 
records for the 54 patients who were reported to have chronic GVHD, only 7 had classic 
chronic GVHD.20 In our analysis, the severity of chronic GVHD was not able to be analyzed 
as the modern NIH classification and grading system for chronic GVHD was developed in 
the midst of the era of transplantation for this group.6 We also did not review or analyze any 
information on treatment for GVHD or response, but this should certainly be studied, 
especially as GVHD after UCBT may respond differently compared to GVHD after 
transplantation from other donor sources.21
In conclusion, acute and chronic GVHD remain significant complications after UCBT with 
severe acute GVHD clearly impacting long-term survival. Rates of acute GVHD appear 
comparable to what is observed with conventional matched donor sources, yet the incidence 
of chronic GVHD appears to be significantly less. In our study, omission of ATG was the 
most important risk factor associated with the development of acute GVHD, and prior acute 
GVHD was the most significant risk factor for the development of chronic GVHD. 
Preventing acute GVHD for patients after UCBT should be a priority and possible avenues 
include formally defining the role of ATG, enhanced or novel GVHD prophylaxis 
regimens22,23 and improving methods of UCB expansion or activation to use better HLA-
matched units.24 While chronic GVHD appears to be less prevalent after UCBT, a future 
analysis should be performed when a large number of patients have been classified 
according to a standard grading scheme where severity of disease can be taken into account 
to truly assess its impact.
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Figure 1. 
Cumulative incidence of grades 2–4 acute GVHD in recipients of single UCBT who 
received ATG (n=521) and those who did not (n=289).
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Figure 2. 
Cumulative incidence of grades 2–4 acute GVHD in recipients of double UCBT who 
received ATG (n=122) and those who did not (n=472).
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Table 1a
Clinical characteristics of patients undergoing single UCBT
Characteristic All With ATG Without ATG p
N 810 521 289
Number of centers 105 88 68
Age, median (range), years 6 (<1–18) 5 (<1–18) 7 (1–18) <0.001
Age at UCBT, years <0.001
 0–4 346 (43%) 248 (48%) 98 (34%)
 5–9 275 (34%) 164 (31%) 111 (38%)
 10–14 148 (18%) 90 (17%) 58 (20%)
 15–17 41 (5%) 19 (4%) 22 (8%)
Gender 0.37
 Male 451 (56%) 284 (55%) 167 (58%)
 Female 359 (44%) 237 (45%) 122 (42%)
Karnofsky/Lansky score 0.66
 < 90 141 (17%) 93 (18%) 48 (17%)
 90–100 669 (83%) 428 (82%) 241 (83%)
Race of recipient 0.03
 Caucasian 469 (58%) 320 (61%) 149 (52%)
 African-American 77 (10%) 49 (9%) 28 (10%)
 Asian/Pacific Islander 45 (6%) 28 (5%) 17 (6%)
 Hispanic 176 (22%) 97 (19%) 79 (27%)
 Native American 11 (1%) 9 (2%) 2 (< 1%)
 Missing 32 (4%) 18 (3%) 14 (5%)
CMV status of recipient 0.16
 Negative 412 (51%) 278 (53%) 134 (46%)
 Positive 391 (48%) 239 (46%) 152 (53%)
 Missing 7 (< 1%) 4 (< 1%) 3 (1%)
Disease <0.001
 AML 356 (44%) 255 (49%) 101 (35%)
 ALL 454 (56%) 266 (51%) 188 (65%)
Disease status at UCBT 0.07
 Early 282 (35%) 182 (35%) 100 (35%)
 Intermediate 412 (51%) 253 (49%) 159 (55%)
 Advanced 114 (14%) 84 (16%) 30 (10%)
 Missing 2 (<1%) 2 (<1%) 0
Donor-Recipient sex match 0.71
 F-M 215 (26%) 141 (27%) 74 (26%)
 F-F 175 (22%) 116 (22%) 59 (20%)
 M-M 234 (29%) 142 (27%) 92 (32%)
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Characteristic All With ATG Without ATG p
 M-F 184 (23%) 121 (23%) 63 (22%)
 Missing 2 (<1%) 1 (<1%) 1 (<1%)
HLA-matching 0.05
 6/6 169 (21%) 111 (21%) 58 (20%)
 5/6 382 (47%) 230 (44%) 152 (53%)
 4/6 259 (32%) 180 (34%) 79 (27%)
Total nucleated cell dose, pre-cryo, median (range) × 107/kg 7 (3–56) 7 (3–50) 6 (3–56) 0.03
Total nucleated cell dose, pre-cryo, × 107/kg <0.001
 3–5 195 (24%) 107 (21%) 88 (30%)
 5–8 223 (28%) 133 (26%) 90 (31%)
 ≥ 8 289 (36%) 205 (39%) 82 (39%)
 Missing 103 (13%) 76 (15%) 27 (9%)
Conditioning regimen
 Myeloablative 810 (100%) 521 (100%) 289 (100%) –
 Reduced Intensity 0 0 0
TBI used 573 (71%) 314 (60%) 259 (90%) <0.001
GVHD prophylaxis <0.001
 CNI + SIRO 34 (4%) 6 (1%) 28 (10%)
 CNI + MMF 327 (40%) 151 (29%) 176 (61%)
 CNI + MTX 102 (13%) 56 (11%) 46 (16%)
 CNI + COR 247 (30%) 220 (42%) 27 (9%)
 CNI ± other 100 (12%) 88 (17%) 12 (4%)
Year of UCBT <0.001
 2003–2005 202 (25%) 184 (35%) 18 (6%)
 2006–2008 288 (36%) 182 (35%) 106 (37%)
 2009–2012 320 (39%) 155 (30%) 165 (57%)
Abbreviations: UCBT = Umbilical Cord Blood Transplant; GVHD = graft-vs.-host disease; CNI = Calcineurin Inhibitor (either Cyclosporine or 
Tacrolimus); SIRO = Sirolimus; MMF = Mycophenolate mofetil; MTX = Methotrexate; COR = Corticosteroids (systemic).
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Table 1b
Clinical characteristics of patients undergoing double UCBT
Characteristic All With ATG Without ATG p
N 594 122 472
Number of centers 87 38 75
Age, median (range), years 42 (18–79) 49 (18–74) 41 (18–79) 0.005
Gender 0.16
 Male 297 (50%) 54 (44%) 253 (51%)
 Female 297 (50%) 68 (56%) 229 (49%)
Karnofsky/Lansky score <0.001
 < 90 171 (29%) 50 (41%) 121 (26%)
 90–100 423 (71%) 72 (59%) 351 (74%)
Race 0.02
 Caucasian 371 (62%) 86 (70%) 285 (60%)
 African-American 69 (12%) 19 (16%) 50 (11%)
 Asian/Pacific Islander 49 (8%) 6 (5%) 43 (9%)
 Hispanic 84 (14%) 8 (7%) 76 (16%)
 Native American 4 (< 1%) 0 4 (< 1%)
 Missing 17 (3%) 3 (2%) 14 (3%)
CMV status of recipient 0.01
 Negative 183 (31%) 25 (20%) 158 (33%)
 Positive 397 (67%) 95 (78%) 302 (64%)
 Missing 17 (3%) 2 (2%) 12 (3%)
Disease 0.006
 AML 428 (72%) 100 (82%) 328 (69%)
 ALL 166 (28%) 22 (18%) 144 (31%)
Disease status at UCBT <0.001
 Early 278 (47%) 46 (38%) 232 (49%)
 Intermediate 225 (38%) 43 (35%) 182 (39%)
 Advanced 91 (15%) 33 (27%) 58 (12%)
Donor-Recipient gender 0.52
 (F,F)-M or (F,M)-M 207 (35%) 38 (31%) 169 (36%)
 All other combinations 343 (58%) 76 (62%) 267 (57%)
 Missing 44 (7%) 8 (7%) 36 (8%)
HLA-matching 0.77
 4/6 + 4/6 251 (42%) 48 (39%) 203 (43%)
 One 4/6 UCB unit 134 (23%) 29 (24%) 105 (22%)
 No 4/6 UCB units 209 (35%) 45 (37%) 164 (35%)
Total nucleated cell dose, pre-cryo, median (range) × 107/kg 5 (3–55) 4 (3–31) 5 (3–55) 0.02
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Characteristic All With ATG Without ATG p
Total nucleated cell dose, pre-cryo, × 107/kg 0.17
 3–5 268 (45) 64 (52%) 204 (43%)
 5–8 190 (32) 31 (25%) 159 (34%)
 ≥ 8 47 (8) 7 (6%) 40 (8%)
 Missing 89 (15) 20 (16%) 69 (15%)
Conditioning Regimen 0.002
 Myeloablative 351 (59%) 57 (47%) 294 (62%)
 Reduced Intensity 243 (41%) 65 (53%) 178 (38%)
TBI used 497 (83%) 60 (49%) 437 (93%) <0.001
GVHD prophylaxis <0.001
 CNI + SIRO 27 (5%) 14 (11%) 13 (3%)
 CNI + MMF 535 (90%) 96 (79%) 439 (93%)
 CNI + MTX 15 (3%) 4 (3%) 11 (2%)
 CNI ± other 17 (4%) 8 (6%) 9 (2%)
Year of UCBT <0.001
 2003–2008 188 (32%) 58 (48%) 130 (28%)
 2009–2012 406 (68%) 64 (52%) 342 (72%)
Abbreviations: UCBT = Umbilical Cord Blood Transplant; GVHD = graft-vs.-host disease; CNI = Calcineurin Inhibitor (either Cyclosporine or 
Tacrolimus); SIRO = Sirolimus; MMF = Mycophenolate mofetil; MTX = Methotrexate; COR = Corticosteroids (systemic).
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Table 2
Cumulative incidences of acute and chronic GVHD
All (95% CI) With ATG (95% CI) Without ATG (95%CI)
Single UCBT 810 521 (64%) 289 (36%)
Cumulative incidence of grades II–IV acute GVHD1 39% (36%–43%) 33% (29%–37%) 50% (44%–56%)
Cumulative incidence of grades III–IV acute GVHD1 18% (15%–20%) 15% (12%–19%) 21% (17%–26%)
Cumulative incidence of chronic GVHD2 27% (24%–30%) 22% (19%–26%) 35% (29%–41%)
Double UCBT 594 122 (21%) 472 (79%)
Cumulative incidence of grades II–IV acute GVHD1 45% (41%–49%) 26% (18–34%) 50% (46%–55%)
Cumulative incidence of grades III–IV acute GVHD1 22% (19%–26%) 16% (10%–23%) 24% (20%–28%)
Cumulative incidence of chronic GVHD2 26% (22%–29%) 21% (15%–29%) 27% (23%–31%)
1Cumulative incidence of acute GVHD calculated through day +100 after UCBT
2Cumulative incidence of chronic GVHD calculated through 1 year after UCBT
Abbreviations: UCBT = umbilical cord blood transplant; GVHD = graft-versus-host disease; ATG = anti-thymocyte globulin
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Table 3a
Effect of acute and chronic GVHD on outcomes after single and double UCBT
Single UCBT Relapse Non-Relapse Mortality Disease-Free Survival Overall Survival
Gr. 2–4 Acute GVHD HR 0.69 (0.51–0.93)p = 0.014
HR 2.06 (1.47–2.88)
p < 0.0001
HR 1.06 (0.86–1.32)
p = 0.58
HR 1.08 (0.87–1.34)
p = 0.50
Gr. 3–4 Acute GVHD HR 0.78 (0.53–1.15)p = 0.22
HR 2.75 (1.92–3.93)
p < 0.0001
HR 1.38 (1.07–1.79)
p = 0.014
HR 1.51 (1.17–1.95)
p = 0.0017
Chronic GVHD HR 1.10 (0.74–1.63)p = 0.63
HR 1.53 (0.97–2.42)
p = 0.068
HR 1.23 (0.91–1.65)
p = 0.18
HR 0.96 (0.72–1.29)
p = 0.82
Double UCBT Relapse Non-Relapse Mortality Disease-Free Survival Overall Survival
Gr. 2–4 Acute GVHD HR 0.87 (0.63–1.20)p = 0.39
HR 1.41 (1.05–1.90)
p = 0.022
HR 1.11 (0.90–1.37)
p = 0.34
HR 1.05 (0.86–1.30)
p = 0.60
Gr. 3–4 Acute GVHD HR 0.68 (0.44–1.06)p = 0.084
HR 2.24 (1.66–3.04)
p < 0.0001
HR 1.41 (1.11–1.79)
p = 0.005
HR 1.48 (1.17–1.86)
p = 0.001
Chronic GVHD HR 0.59 (0.36–0.96)p = 0.033
HR 1.49 (0.98–2.29)
p = 0.065
HR 0.98 (0.71–1.33)
p = 0.87
HR 0.95 (0.71–1.27)
p = 0.70
Abbreviations: UCBT=Umbilical Cord Blood Transplant; GVHD = Graft-vs.-Host Disease; Gr. = Grade
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Table 4a
Summary of studies analyzing risk factors for acute GVHD after UCBT
Study Population Incidence of grades II–IV acute GVHD
Incidence of grades III–IV 
acute GVHD Risk Factors
Macmillan et al.11
Single UCBT
(n=80) 39% 18% Use of 2 UCB units
NMA conditioning regimen
No ATGDouble UCBT
(n=185) 58% 19%
Lazaryan et al.10
Single UCBT
(n=295) 26% 7%
Age ≥ 18
Higher HLA-mismatcha
Double UCBT
(n=416) 56% 21%
No ATGa
Year of UCBT 2006 or latera
Higher HLA-mismatchb
Myeloablative conditioningb
Ponce et al.13 Double UCBT(n=115) 53% 23% Higher HLA-mismatchb
Xavier et al.12 Double UCBT(n=921) 36% 15%
Myeloablative conditioninga
Higher HLA-mismatcha
No ATG
Advanced disease stageb
Chen et al.
Single UCBT
(n=810) 39% 18% No ATG
Double UCBT
(n=594) 45% 22%
No ATGa
Myeloablative conditioning
Abbreviations: GVHD = graft-vs.-host disease; UCBT = umbilical cord blood transplantation; UCB = umbilical cord blood; NMA = non-
myeloablative; ATG = anti-thymocyte globulin; HLA = human leukocyte antigen; iv-TCD = in vivo T-cell depletion
aOnly for grades II–IV acute GVHD
bOnly for grades III–IV acute GVHD
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Table 4b
Summary of studies analyzing risk factors for chronic GVHD after UCBT
Study Population Incidence of chronic GVHD Risk Factors
Macmillan et al.11
Single UCBT
(n=80) 18%
Prior grades II–IV acute GVHD
Double UCBT
(n=185) 17%
Lazaryan et al.10
Single UCBT
(n=295) 7%
Age ≥ 18
Non-use of cyclosporine/MMF for GVHD prophylaxis
Double UCBT
(n=416) 26%
Higher HLA-mismatch
Myeloablative conditioning
Prior grades II–IV acute GVHD
Ponce et al.13 Double UCBT(n=115) 23% Not reported
Narimatsu et al.14 Single UCBT(n=1072) 28%
Higher recipient body weight
Higher HLA-mismatch
Myeloablative conditioning
Use of mycophenolate mofetil
Prior grades II–IV acute GVHD
Xavier et al.12 Double UCBT(n=921) 25%
Higher HLA-mismatch
Prior grades II–IV acute GVHD
Chen et al.
Single UCBT
(n=810) 27%
Prior grades II–IV acute GVHD
Double UCBT
(n=594) 26%
Abbreviations: GVHD = graft-vs.-host disease; UCBT = umbilical cord blood transplantation; UCB = umbilical cord blood; MMF = 
mycophenolate mofetil; ATG = anti-thymocyte globulin; HLA = human leukocyte antigen; iv-TCD = in vivo T-cell depletion
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